Related Experiment Video
Updated: Jun 27, 2025
08:53
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
826
Recombinant probiotic Lactococcus lactis delivering P62 mitigates moderate colitis in mice
Juliana Guimarães Laguna1, Andria Dos Santos Freitas1, Fernanda Alvarenga Lima Barroso1
1Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Frontiers in Microbiology
|April 29, 2024
Summary
Recombinant probiotics delivering p62 protein protected the intestinal mucosa and reduced inflammation in a mouse model of ulcerative colitis. This suggests p62 is a potential therapeutic target for inflammatory bowel diseases.
Area of Science:
- Microbiology
- Immunology
- Gastroenterology
Background:
- p62 is a multifunctional adaptor protein that negatively regulates inflammasome complexes.
- p62 shows therapeutic potential for inflammatory bowel diseases (IBD) like colitis.
- Recombinant probiotics can deliver therapeutic biomolecules to mitigate intestinal inflammation.
Purpose of the Study:
- To combine the probiotic Lactococcus lactis NCDO2118 with p62 delivery for enhanced ulcerative colitis (UC) treatment.
- To evaluate the protective and preventive effects of this combined approach in a UC model.
Main Methods:
- In vivo study using mice supplemented with recombinant L. lactis NCDO2118.
- Analysis of intestinal barrier function, integrity, and inflammation markers (cytokines, MPO).
- Investigation of intestinal microbiota composition using 16S rRNA Gene Sequencing.
Main Results:
- Recombinant L. lactis NCDO2118 expressing p62 increased goblet cell counts and Muc2 expression.
- Downregulation of pro-inflammatory cytokines (Tnf, Ifng) and MPO activity in the colon.
- No significant changes in clinical parameters or intestinal microbiota were observed.
Conclusions:
- Recombinant L. lactis NCDO2118 delivering p62 protected intestinal mucosa and mitigated DSS-induced inflammatory damage.
- p62 protein shows promise as a therapeutic agent for targeting intestinal inflammation.
- Further research into p62-based therapies for IBD is warranted.
